Please assess the completion status of the following clinical trial:

Trial Title: Neostigmine Treatment of Acute Pancreatitis Combined With Intra-abdominal Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18-70 year ;~2. The diagnosis of acute pancreatitis according to the revised Atlanta classification.~3. IAH is defined as IAP ≥ 12 mmHg by the World Society of Abdominal;Compartment Syndrome (WSACS);~4. After 24 hours of conventional treatment(such as gastrointestinal decompression or percutaneous drainage of ascites), the IAP of AP patients with IAH was still ≥ 12 mmHg;~5. The onset time of acute pancreatitis was within 2 weeks;~6. Signed the informed consent.~Exclusion Criteria:~1. Previous history of laparotomy;~2. Mechanical ileus or abdominal hemorrhage were considered clinically;~3. Those who have contraindications to neostigmine: 1) Patients with angina; 2) myocardial infarction; 3) ventricular tachycardia; 4) bradycardia; 5) acute circulatory failure; 6) epilepsy; 7) bronchial asthma; 8) mechanical intestinal obstruction; 9) urinary tract infarction; 10) hyperthyroidism; 11) serious arrhythmia; 12) bladder operation; 13) intestinal fistula;~4. Allergic to neostigmine;~5. Pregnant or lactating patients.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Neostigmine (Type: EXPERIMENTAL): Intramuscular injection of neostigmine on the basis of conventional conservative treatment
- Conservative treatment (Type: OTHER): Intragastric administration of paraffin oil, 50ml,once every 8 hours；gastrointestinal decompression with nasogastric tube and rectal tub; lycerin enema promotes defecation; patients with ascites undergo percutaneous puncture drainage. Other conservative medical treatment recommended by the guidelines.

Based on this trial design, predict the completion outcome and termination type (if applicable).